AI & Tech
Socher says Parallel Bio won FDA clearance to skip animal tests
Peter Diamandis
Recursive's $670M Bet on Self-Improving AI, Sonnet 5.5 Hits 70%, Elon Co-Leads Pentagon Push EP 299
What was said
"They build tiny organoids on a petri dish, right? And get this, if you love animals, you too can love AI. Why? Because they got FDA approval to skip animal trials. Turns out we cured most diseases in mice. It's not that helpful."
Richard Socher says organoid-testing firm Parallel Bio has received FDA approval to skip animal trials, a claim that remains unverified. He argues lab-grown organoids can predict human drug responses and toxicity better than mouse models.
Verification status
Attributed speaker claim
Egleze verified who said this and where. The underlying claim has not been independently established by Egleze.
Source and context
Egleze verified who said this and where. The underlying claim has not been independently established by Egleze.
- Speaker
- Richard Socher · guest
- Programme
- Peter Diamandis
- Episode
- Recursive's $670M Bet on Self-Improving AI, Sonnet 5.5 Hits 70%, Elon Co-Leads Pentagon Push EP 299
- Clip time
- 17:17
- Original source
- Watch the source segment →
From this episode
Peter Diamandis